Format

Send to

Choose Destination
J Clin Lipidol. 2010 May-Jun;4(3):165-72. doi: 10.1016/j.jacl.2010.01.008.

Cost-effectiveness of lower targets for blood pressure and low-density lipoprotein cholesterol in diabetes: the Stop Atherosclerosis in Native Diabetics Study (SANDS) .

Author information

1
Phoenix Indian Medical Center, 4212 N 16th Street, Phoenix, AZ 85016, USA. Charlton.wilson@ihs.gov

Abstract

BACKGROUND:

The Stop Atherosclerosis in Native Diabetics Study (SANDS) reported cardiovascular benefit of aggressive versus standard treatment targets for both low-density lipoprotein cholesterol (LDL-C) and blood pressure (BP) in diabetic individuals.

OBJECTIVE:

In this analysis, we examined within trial cost-effectiveness of aggressive targets of LDL-C ≤70 mg/dL and systolic BP ≤115 mmHg versus standard targets of LDL-C ≤100 mg/dL and systolic BP ≤130 mmHg.

DESIGN:

Randomized, open label blinded-to-endpoint 3-year trial.

DATA SOURCES:

SANDS clinical trial database, Quality of Wellbeing survey, Centers for Medicare and Medicaid Services, Wholesale Drug Prices.

TARGET POPULATION:

American Indians ≥ age 40 years with type 2 diabetes and no previous cardiovascular events.

TIME HORIZON:

April 2003 to July 2007.

PERSPECTIVE:

Health payer.

INTERVENTIONS:

Participants were randomized to aggressive versus standard groups with treatment algorithms defined for both.

OUTCOME MEASURES:

Incremental cost-effectiveness.

RESULTS OF BASE-CASE ANALYSIS:

Compared with the standard group, the aggressive group had slightly lower costs of medical services (-$116) but a 54% greater cost for BP medication ($1,242) and a 116% greater cost for lipid-lowering medication ($2,863), resulting in an increased cost of $3,988 over 3 years. Those in the aggressively treated group gained 0.0480 quality-adjusted life-years (QALY) over the standard group. When a 3% discount rate for costs and outcomes was used, the resulting cost per QALY was $82,589.

RESULTS OF SENSITIVITY ANALYSIS:

The use of a 25%, 50%, and 75% reduction in drug costs resulted in a cost per QALY of $61,329, $40,070, and $18,810, respectively.

LIMITATIONS:

This study was limited by use of a single ethnic group and by its 3-year duration.

CONCLUSIONS:

Within this 3-year study, treatment to lower BP and LDL-C below standard targets was not cost-effective because of the cost of the additional medications required to meet the lower targets. With the anticipated availability of generic versions of the BP and lipid-lowering drugs used in SANDS, the cost-effectiveness of this intervention should improve. Published by Elsevier Inc on behalf of the National Lipid Association.

PMID:
20563294
PMCID:
PMC2885818
DOI:
10.1016/j.jacl.2010.01.008
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center